



Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: May 23, 2026

To,
Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Scrip Code: 540788
Security ID: ASPIRA

Sub: Outcome of the meeting of Board of Directors held on Saturday, May 23, 2026

Dear Sir/Madam,

In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on Saturday, May 23, 2026 inter alia, has considered, approved and taken on record the following matter(s):

1. The Audited Standalone Financial Results for the fourth Quarter and year ended March 31, 2026 along with the Auditor's Report.

In respect of the above, we hereby enclose the following:

- i. The Audited Standalone Financial results for the fourth quarter and year ended on March 31, 2026, in the format specified under Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
 - ii. Auditor's Report issued by the statutory Auditors of the Company on the Audited Standalone Financial results for the fourth quarter and year ended on March 31, 2026
 - iii. Unmodified Opinion under Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015 for the quarter and financial year ended March 31, 2026
2. Appointment of Appointment of Company Secretary and Compliance Officer: The Board of Directors has approved the appointment of Mrs. Neetu Maurya as the Company Secretary and Compliance Officer of the Company, from 24th May 2026.
 3. Appointment of M/s. Vishal J Bhanushali & Associates, Practicing Chartered Accountant (Firm Registration Number: 145806W), having Membership No. 179979, as an Internal Auditor of the Company for the Financial year 2026-2027.
 4. The Board approved the appointment of Mr. Vaibhav Odhekar (DIN: 05135001) as Additional Executive Director, for a tenure of Five years commencing from date of appointment subject to approval of the shareholders

Pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/ CML/2018/24, both dated 20th June 2018, we confirm that above Mr. Vaibhav Odhekar are not debarred from holding the office of Director by virtue of order of SEBI or any other such authority

INDIA'S FIRST
FULLY INTEGRATED LAB

☎ 0227197 5756, 022 2513 9090 🌐 www.aspiradiagnostics.com
✉ support@aspiradiagnostics.com | info@aspiradiagnostics.com



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086

Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086

CIN: L85100MH1973PLC289209

The detailed disclosure pursuant Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith in "Annexure-I".

The meeting of the Board of Directors commenced at 2.20 p.m. and concluded at 04.35 p.m.

Kindly take the same on record.

Thanking you

Yours Faithfully,
For **Aspira Pathlab and Diagnostics Limited**

Nikunj Velji Digitally signed by
Nikunj Velji Mange
Mange Date: 2026.05.23
18:19:49 +05'30'

Nikunj Mange
Executive Director
DIN: 08489442



Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Annexure-I

Details under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. no.	Particulars	Company Secretary	Internal Auditor	Mr. VAIBHAV ODHEKAR (DIN: 05135001) As Additional Executive Director
1.	Reason for change viz. Appointment	Appointment of Mrs. Neetu Maurya as a Company Secretary & Compliance Officer of the company from May 24, 2026.	Appointment of M/s. Vishal J Bhanushali & Associates, Practicing Chartered Accountant (FRN: 145806W) as Internal Auditor of the Company.	Appointment of Mr. VAIBHAV ODHEKAR as Additional Executive Director of the company from May 23, 2026
2.	Date of Appointment & term of appointment	The Board of Directors at its meeting held on May 23, 2026 approved the appointment of Mrs. Neetu Maurya as a Company Secretary & Compliance Officer of the company from May 24, 2026	The Board of Directors at its meeting held on May 23, 2026 approved the appointment M/s. Vishal J Bhanushali & Associates, as Internal Auditor of the Company for conducting Internal audit for a period of one (1) year, commencing from April 1, 2026, to March 31, 2027.	The Board of Directors at its meeting held on May 23, 2026 approved the appointment Mr. Vaibhav Odhekar as Additional Executive Director for a period of one (5) year, commencing from May 23, 2026.
3.	Brief Profile	Mrs. Neetu Maurya is an Associate Member of Institute of Company Secretaries, India. She has Comprehensive understanding of company law and secretarial, corporate based compliances in Company.	M/s. Vishal J Bhanushali & Associates, Practicing Chartered Accountant: Mr. Vishal Bhanushali, is the Partner of M/s. Vishal J Bhanushali & Associates & a member of the Institute of the Chartered Accountants of India (ICAI). They are engaged in providing quality auditing, assurance, taxation, and advisory services across different verticals to all categories of clients.	Mr. Vaibhav Odhekar is a seasoned entrepreneur and business executive with over 20 years of experience in technology-led platform businesses across India, Southeast Asia and the Middle East. He is the Co-founder of POKKT, one of APAC's leading mobile gaming monetization platforms, which was later merged with AnyMind Group, Japan, culminating in a Tokyo Stock Exchange listing. He has extensive experience in strategic growth, fundraising, cross-border operations, governance, mergers & acquisitions and scaling high-growth organizations. Mr. Vaibhav Odhekar has also served in leadership positions at AnyMind Group and Zapak Digital Entertainment Group and is actively involved as an



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086

Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086

CIN: L85100MH1973PLC289209

				angel investor and advisor to emerging technology and consumer-focused businesses. He holds an MBA from Indian Institute of Management (IIM), Lucknow and a Bachelor of Engineering degree from Bhilai Institute of Technology, Durg.
4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable	Not Applicable	He is not related to any of the Directors/Key Managerial Personnel of the Company
5.	Terms of Appointment	Not Applicable	1 Years	5 years



Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED (“THE COMPANY”) IN ITS MEETING HELD ON SATURDAY, MAY 23, 2026 THROUGH VIDEO CONFERENCING COMMENCED AT 2.20 P.M (IST)

AUTHORISATION FOR SIGNING THE ADUITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2026

“**RESOLVED THAT** pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited financial results for the fourth quarter and financial year ended March 31,2026 be and is hereby approved.

RESOLVED FURTHER THAT pursuant to regulation 33(2)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid audited financial results for the fourth quarter and financial year ended March 31,2026”.

**For and on behalf of
Aspira Pathlab & Diagnostics Limited**

Nikunj
Velji
Mange

Digitally signed by
Nikunj Velji Mange
Date: 2026.05.23
18:20:13 +05'30'

**Nikunj Mange
Executive Director**

DIN: 08489442

**INDIA'S FIRST
FULLY INTEGRATED LAB**

☎ 0227197 5756, 022 2513 9090 🌐 www.aspiradiagnostics.com
✉ support@aspiradiagnostics.com | info@aspiradiagnostics.com



Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Independent Auditors' Report on Quarterly and Annual Audited Financial Results pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

To
The Board of Directors of
Aspira Pathlab & Diagnostics Limited

Opinion

We have audited the accompanying Statement of Financial results of Aspira Pathlab & Diagnostics Limited (the "Company") for the quarter and year ended 31st March, 2026 (refer 'Other Matters' section below) together with the notes thereon ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the annual financial results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the annual financial results.



11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.

Phone: 022-2269 5289 ; Mobile: 98191 65816

Email: ssaudit2102@gmail.com / sardasoniassociates2102@gmail.com

Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.

Phone: 0712-2726795, 2729471

Management's and Board of Directors' Responsibilities for the Annual Financial Results

The annual financial results have been prepared on the basis of the annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit/(loss) and other comprehensive income/(loss) and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- (i) Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



-
- (ii) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - (iii) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial results made by the Management and Board of Directors.
 - (iv) Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - (v) Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.



Other Matters


- (1) The Management of the Company has represented that pursuant to the Slump Sale Agreement effective 30 June 2025, the business undertaking of Aspira DNA Diagnostics Gujarat LLP was transferred to the Company and the LLP ceased substantive business operations thereafter. Management has further represented that no significant economic activities were carried out by the LLP subsequent to the transfer date and that the LLP continued to exist only for completion of procedural winding-up formalities. Accordingly, based on the principle of substance over legal form, management has concluded that the associate relationship effectively ceased from 30 June 2025 and, therefore, Consolidated Financial Statements have not been prepared for the year ended 31 March 2026.
- (2) During the quarter ended 31st March, 2026, the Company has acquired the business undertaking of **Om Pathology Laboratory**, Surat on a going concern basis pursuant to a Business Transfer Agreement (BTA) effective 01 February 2026. The acquisition includes transfer of operational business infrastructure and related assets.

The transaction has been accounted for in accordance with applicable Indian Accounting Standards (Ind AS). Deferred consideration, where applicable, has been recognised at fair value and subsequently measured at amortised cost using the effective interest rate method. The excess of consideration over identifiable net assets acquired has been recognised as Goodwill, which is subject to annual impairment testing in accordance with Ind AS 36 – Impairment of Assets.

The annual financial results include the results for the quarter ended 31 March 2026 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to nine months ended 31st December, 2025 which were subject to limited review by us.



For Sarda Soni Associates LLP
Chartered Accountant
Firm Reg. No- 117235W


Manoj Kumar Jain

Partner
Membership No.-120788
Place- Mumbai
Date- 23.05.2026
UDIN: 26120788JNCYTH7739

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086
Tel No. 022-71975756, Email:support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Statement of Financial Results for the Quarter and Year ended 31st March, 2026


Particulars	(Rupees in Lakhs)				
	Quarter ended			Year ended	Year ended
	31-Mar-26 (Unaudited) (Refer Note 3)	31-Dec-25 (Unaudited) (Refer Note 3)	31-Mar-25 (Unaudited) (Refer Note 3)	31-Mar-26 (Audited)	31-Mar-25 (Audited)
1. Income					
(a) Revenue from Operations	652.24	511.88	577.67	2,498.20	2,199.90
(b) Other Income	13.92	12.94	13.04	51.59	38.89
Total income	666.17	524.83	590.71	2,549.79	2,238.79
2. Expenses					
(a) Cost of Materials consumed	121.98	112.19	86.95	452.04	369.58
(b) Laboratory Testing Charges	37.75	34.86	25.09	133.56	99.65
(c) Employee benefits expense	228.97	245.07	194.41	877.68	732.62
(d) Finance Costs	9.97	9.81	9.32	38.94	34.74
(e) Depreciation and amortisation expense	39.54	38.23	36.74	153.84	149.38
(f) Other expenses	296.86	240.79	165.87	888.60	645.57
Total Expenses	735.07	680.95	518.37	2,544.67	2,031.53
3. Profit / (Loss) before exceptional items and tax (1-2)					
	(68.90541)	(156.12)	72.33	5.13	207.26
4. Exceptional Items	-	-	-	-	-
5. Profit / (Loss) before tax (3+4)	(68.91)	(156.12)	72.33	5.129078	207.26
6. Tax Expenses	-	-	-	-	-
7. Profit / (Loss) after tax (5-6)	(68.91)	(156.12)	72.33	5.13	207.26
8. Other Comprehensive income(net of tax)	6.12	-	0.04	6.12	0.04
9. Total Comprehensive income/ (Loss) (7+8)	(62.79)	(156.12)	72.37	11.25	207.30
10. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30
11. Other Equity	-	-	-	193.80	192.34
12. Earnings per share (in Rupees)					
(a) Basic	(0.67)	(1.52)	0.70	0.05	2.01
(b) Diluted	(0.67)	(1.52)	0.70	0.05	2.01

Notes

- The above financial results of the Company for the quarter and Year ended March 31, 2026 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 23rd May, 2026.
- These financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December 2025 and 31 December 2024 respectively, which was subjected to limited review.
- Business Acquisition and Consolidation Status:**
During the financial year the Company has acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for a consideration of ₹13.00 lakhs, effective from the end of business day on 30th June 2025, pursuant to a Business Transfer Agreement (BTA). The LLP has ceased business operations and is in the process of winding up under the LLP Act, 2008. Accordingly, applying the principle of substance over legal form and based on management's assessment of materiality and economic substance, the LLP has not been considered as an associate for the purpose of preparation of financial statements subsequent to 30 June 2025. Consequently, the Company has not prepared Consolidated Financial Statements for the year ended 31 March 2026, as management believes that no subsidiary, associate or joint venture relationship of substantive economic significance existed as at the reporting date requiring consolidation in accordance with applicable Indian Accounting Standards.
- During the quarter/year, the Company has acquired the business undertaking of Om Pathology Laboratory, Surat on a going concern basis pursuant to a Business Transfer Agreement (BTA) effective 01 February 2026. The acquisition includes transfer of operational business infrastructure and related assets. The transaction has been accounted for in accordance with applicable Indian Accounting Standards (Ind AS). Deferred consideration, where applicable, has been recognised at fair value and subsequently measured at amortised cost using the effective interest rate method. The excess of consideration over identifiable net assets acquired has been recognised as Goodwill, which is subject to annual impairment testing in accordance with Ind AS 36 – Impairment of Assets.
- Disclosure of segment wise information is not applicable, as pathology services is the Company's only business segment.
- The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Executive Director
DIN: 08489442
Place: Mumbai
Date: 23.05.2026



For Sarda Soni Associates LLP
Chartered Accountants
Firm's Registration No.:117235W
CA Manoj Kumar Jain
Partner
Membership No.:120788
Date: 23.05.2026

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN : L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Tel No. 022-71975756, Email:support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Balance Sheet as at 31 March 2026

(Rupees in Lakhs)

Particulars	As at	As at
	31 March 2026 (Audited)	31 March 2025 (Audited)
A ASSETS		
Non-current assets		
Property, plant and equipment	206.38	207.72
Right of Use Assets	181.77	178.42
Goodwill	330.56	265.18
Other Intangible assets	1.52	1.41
Financial Assets		
(i) Investments in associates	-	13.00
(ii) Loans and advances	358.49	334.59
(iii) Others	313.33	214.38
Total non-current assets	1,392.05	1,214.70
Current Assets		
Inventories	69.72	51.13
Financial Assets		
(i) Trade Receivables	173.42	235.16
(ii) Cash and Cash Equivalents	126.46	175.24
(iii) Bank balances other than (ii) above	41.55	39.16
(iv) Others financial assets	2.50	1.18
Current tax assets (net)	23.77	19.33
Other Current Assets	21.11	15.24
Total Current Assets	458.52	536.44
Total Assets	1,850.57	1,751.15
B EQUITY AND LIABILITIES		
EQUITY		
Equity share Capital	1,029.30	1,029.30
Other equity	193.80	192.34
Total Equity	1,223.10	1,221.64
LIABILITIES		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	135.12	120.64
(ii) Lease liabilities	109.35	116.28
Provisions	63.43	55.36
Total non-current liabilities	307.90	292.28
Current liabilities		
Financial liabilities		
(i) Borrowings	-	-
(ii) Lease liabilities	87.76	82.68
(iii) Trade payables		
Total outstanding dues of micro and small enterprises	44.45	17.78
Total outstanding dues of creditors other than micro and small enterprises	69.58	56.02
(iv) Other financial liabilities	88.69	60.73
Other current liabilities	17.61	15.30
Provisions	11.49	4.73
Total current Liabilities	319.58	237.23
Total Liabilities	627.47	529.51
Total Equity and Liabilities	1,850.57	1,751.15

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

For Sarda Soni Associates LLP
Chartered Accountants

Firm's Registration No.: 117235W


Nikunj Mange

Executive Director

DIN: 08489442

Place: Mumbai

Date: 23.05.2026



Manoj Kumar Jain

Partner

Membership No.:120788

Date :23.05.2026

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Cash Flow Statement for the year ended 31st March 2026

(All amounts in Lakhs, unless otherwise stated)

Particulars	For the year ended	
	31.03.2026 (Audited)	31.03.2025 (Audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit/(Loss) for the year		
Adjustments for:	5.13	207.26
Interest income		
Deposit W/off	(51.59)	(36.90)
Loss on Sale of Fixed Asset	1.00	-
Finance Costs	-	(3.24)
Depreciation and amortisation expenses	38.94	34.74
Remeasurement of defined benefit plans	153.84	149.38
Profit on lease termination	6.12	0.04
Provision for impairment of trade receivables and advances	1.30	0.12
	31.87	33.38
Operating profit before working capital changes		
Working capital adjustments:	186.62	384.77
(Increase)/Decrease in Trade receivables	29.87	(44.32)
(Increase)/Decrease in Inventories	(18.59)	(6.41)
(Increase)/Decrease in other Non-Current advances	(26.23)	(12.75)
(Increase)/Decrease in Current Assets, Loans & advances and Other non-current assets	(101.34)	(160.81)
(Increase)/Decrease in other Current Assets	(10.29)	(4.27)
Increase/(Decrease) in Trade payables	40.23	1.14
Increase/(Decrease) in Provisions	14.83	15.73
Increase/(Decrease) in other Current and non-current Liabilities	2.31	4.32
Increase/(Decrease) in Other financial liabilities	27.96	10.30
CASH GENERATED FROM OPERATIONS	145.36	187.70
Taxes Paid (net of refunds)	-	-
NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)	145.36	187.70
B CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(69.57)	(34.43)
Purchase of Intangible assets	(0.29)	-
Acquisition of business (net of cash acquired)		
(Increase)/Decrease in Investments	(75.16)	(13.00)
Proceeds from sale of fixed assets	-	17.11
Interest Received	51.59	36.90
NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)	(80.43)	6.58
C CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of long term borrowings	14.48	12.93
Repayment of short-term borrowings	-	-
Principal payment of Lease Liability	(89.25)	(77.61)
Interest paid on lease liabilities	(18.68)	(17.60)
Interest paid	(20.27)	(17.14)
NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)	(113.72)	(99.42)
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(48.78)	94.86
Add: Cash and Cash Equivalents at the beginning of the year	175.24	80.38
Less: Cash Credits at the beginning of the year	-	-
Adjusted cash & cash equivalents at the beginning of the year	175.24	80.38
Cash and Cash Equivalents at the end of the year	126.46	175.24
Components of cash and cash equivalents comprise:		
Cash in hand	5.31	12.00
Balances with banks:		
in Current Accounts	120.90	163.22
in Escrow Account	0.25	0.03
in Cash Credit Accounts	-	-
Deposits with maturity less than 3 months	-	-
Cash and Cash Equivalents in cash flow statement	126.46	175.24

- Note:**
- 1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
 - 2) The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7 Statement of Cash Flows.
 - 3) The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Executive Director
DIN: 08489442
Place: Mumbai
Date: 23.05.2026



For Sarda Soni Associates LLP
Chartered Accountants
Firm's Registration No.: 117235W

CA Manoj Kumar Jain
Partner
Membership No.:120788
Date :23.05.2026



Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand
Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction
LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: May 23, 2026

To,
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Scrip Code: 540788
Security ID: ASPIRA

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

Dear Sir/ Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company i.e M/s. Sarda Soni Associates LLP, Chartered Accountants, (Firm Reg. No. 117235W) have issued an Audit Report on the Standalone Financial Results of the Company for the quarter and year ended March 31, 2026 with unmodified opinion.

Kindly take the same on your record.

Thanking you.

For **Aspira Pathlab & Diagnostics Limited**

Balkrishna Talawadekar
Chief Financial Officer

INDIA'S FIRST
FULLY INTEGRATED LAB

☎ 0227197 5756, 022 2513 9090 🌐 www.aspiradiagnostics.com
✉ support@aspiradiagnostics.com | info@aspiradiagnostics.com



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: May 23, 2026

To,
Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Scrip Code: 540788
Security ID: ASPIRA

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of provisions of Regulation 10(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31 December 2024, and BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2 January 2025; the Integrated Filing (Financial) for the quarter and year ended 31 March, 2026 is enclosed herewith.

Kindly take the same on records

For **ASPIRA PATHLAB & DIAGNOSTIC LIMITED**

Nikunj Velji
Mange

Digitally signed by
Nikunj Velji Mange
Date: 2026.05.23
18:21:15 +05'30'

Nikunj Mange
Executive Director
DIN: 08489442

INDIA'S FIRST
FULLY INTEGRATED LAB

☎ 0227197 5756, 022 2513 9090 🌐 www.aspiradiagnostics.com
✉ support@aspiradiagnostics.com | info@aspiradiagnostics.com



Aspira Pathlab & Diagnostics Limited
Registered Office: Flat No. 2, R D Shah Building, Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

A. Financial Result – Annexure A

B. Statement on deviation or variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: **Not Applicable**

C. Format for disclosing outstanding default on Loans and Debt Securities: **Not Applicable as we don't have any default on loans and debt securities outstanding as on March 31, 2026**

Sr. No.	Particulars	in ₹ crore
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short term and long-term debt	0

D. Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter): **Applicable for this Quarter**

Sr. No.	Details of the party (Stockholder/ subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transactions	Value of the related party transactions approved by the audit committee	Value of the related party transactions approved by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transactions during the reporting period	In accordance with the listed entity's policy	
	Name	PIN	Name	PIN	Relationship of the counterparty with the listed entity or its subsidiary							Spending balance	Claim balance
1	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Mrs. Deepali Arvind Bhatnagar	ASPIR042P	Relative of Promoter	Remuneration					0.02	1.80	1.80
2	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Tatling Biotech India Private Limited	ASPIR049C	Promoter Group	Sole of goods services					16.34	2.01	18.01
3	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Omnesys Global Private Limited	ASPIR042T	Entrepreneurial Risk Manager of Promoter's close relative and significant influence	Sole of goods services					0.00	4.15	4.15
4	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Dr. Sushil Shah	ASPIR049H	Relative of Managing Director & CEO	Any other transaction	Production of Consultancy Fee				0.39	1.05	1.05
5	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Dr. Pankaj Shah	ASPIR049B	Managing Director & CEO	Any other transaction	Post-Equity				0.00	1.25	1.25
6	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Smt. Shalini J. Shah	ASPIR049I	Relative of Managing Director & CEO	Any other transaction	Post-Equity				16.20	2.94	2.94
7	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Obertec Financial Management Private Limited	ASPIR042D	Common Director	Sole of goods services					0.25	0.68	0.68
8	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Tatling Biotech India Private Limited	ASPIR049C	Promoter	Any other transaction	Post-Equity				0.00	0.00	0.00
9	Aspira Pathlab & Diagnostics Limited	ASPIR0496	Tatling Research Foundation	ASPIR042E	Common Promoter of Board Director	Sole of goods services					67.04	0.00	0.00



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086

Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086

CIN: L85100MH1973PLC289209

E. Statement on Impact of Audit Qualifications (for Audit Report with unmodified opinion) submitted along-with annual Audited Financial Results (Standalone) (applicable only for Annual Filing i.e., 4th quarter): **Applicable for this Quarter**

**INDIA'S FIRST
FULLY INTEGRATED LAB**

☎ 0227197 5756, 022 2513 9090 🌐 www.aspiradiagnostics.com
✉ support@aspiradiagnostics.com | info@aspiradiagnostics.com